Skip to main content
. 2014 Mar;99(3):458–464. doi: 10.3324/haematol.2013.095158

Figure 3.

Figure 3.

Cumulative incidence of complete molecular response (CMR) in patients who achieved complete cytogenetic response (CCyR) at 12 months of imatinib (IM) therapy or later (A), in patients who achieved CCyR and major molecular response (MMR), CCyR and no MMR at 12 months and CCyR after 12 months of IM therapy (B), and in patients who achieved MMR or not at 18 months of IM therapy (C).